A Vanderbilt study found that a drug that has been used for decades for intestinal pinworms, can be repurposed as a preventative treatment for stomach cancer.

Researchers at Vanderbilt University Medical Center have uncovered evidence of fibroblast cells' direct involvement in the development of gastric cancer.

Vanderbilt's James Goldenring, MD, PhD, has been honored by the American Gastroenterological Association for making significant contributions to understanding gastrointestinal disease.

The Gastric Cancer Foundation has awarded a one-year $100,000 research grant to Eunyoung Choi, PhD, to support her efforts to find a way to disrupt the transformation of dysplastic stem cells into stomach cancer.

Vanderbilt researchers have received $5 million in funding from a new initiative by the National Cancer Institute that aims to define how gastric and gastroesophageal junction adenocarcinomas form and evolve at the cellular level.

Eunyoung Choi, PhD, assistant professor of Surgery, and colleagues identified for the first time that Trop2+/CD133+/CD166+ dysplastic stem cells are a key source of clonal evolution of dysplasia to multiple types of gastric cancer.

Two Vanderbilt researchers have received awards from the AGA Foundation, the charitable arm of the American Gastroenterological Association.